Literature DB >> 8625539

Parvovirus infection and its treatment.

N S Young1.   

Abstract

B19 parvovirus is an important pathogen in man. Acute infection produces fifth disease (erythema infectiosum) in normal individuals, transient aplastic crisis in the patient with haemolysis, and pure red cell aplasia in the immunologically incompetent host. Fetal infection can lead to hydrops fetalis. The target cell of the virus is the marrow erythroid progenitor. The immune response to the virus is largely humoral and directed against limited numbers of epitopes. Persistent infection is due to failure to produce neutralizing antibodies. Because viral infection is prevalent in the population, therapeutic immune globulin preparations are a good source of anti-B19 antibodies. IgG administration can lead to cure of anaemia in the congenitally immunodeficient patient and to its amelioration in AIDS patients with persistent parvovirus infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625539

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  [Outbreak of infectious erythema at a urban health center].

Authors:  A I Revilla Grande; T Carro García; M Sánchez de Dios; M J Galán Calvo; T Nebreda Mayoral
Journal:  Aten Primaria       Date:  2000 Jul-Aug       Impact factor: 1.137

Review 3.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

4.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 5.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  High-Throughput Screening Identifies Inhibitors for Parvovirus B19 Infection of Human Erythroid Progenitors.

Authors:  Kang Ning; Anuradha Roy; Fang Cheng; Peng Xu; Steve Kleiboeker; Carlos R Escalante; Jingxin Wang; Jianming Qiu
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

7.  Evaluation of a real-time PCR assay using the LightCycler system for detection of parvovirus B19 DNA.

Authors:  Richard S Buller; Gregory Storch
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia.

Authors:  Shigeki Ito; Tatsuo Oyake; Toshiyuki Uchiyama; Takeshi Sugawara; Kazunori Murai; Yoji Ishida
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

9.  Pure red cell aplasia associated with parvovirus B19 infection in a patient with ulcerative colitis.

Authors:  Hajime Isomoto; Yasuhiro Fukuda; Yumiko Bando; Ikuko Machida; Haruhisa Machida; Katsuhisa Omagari; Yohei Mizuta; Kunihiko Murase; Takuya Fukushima; Ikuo Murata; Shigeru Kohno
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.487

Review 10.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.